Iteos Therapeutics Stock Fundamentals
| ITOSDelisted Stock | USD 10.15 0.00 0.00% |
Fundamental analysis of Iteos Therapeutics allows traders to better anticipate movements in Iteos Therapeutics' stock price by examining its financial health and performance throughout various phases of its business cycle.
Iteos |
Iteos Therapeutics Company Current Valuation Analysis
Iteos Therapeutics' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Iteos Therapeutics Current Valuation | (61.62 M) |
Most of Iteos Therapeutics' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Iteos Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
CompetitionIn accordance with the recently published financial statements, Iteos Therapeutics has a Current Valuation of (61.62 Million). This is 100.43% lower than that of the Biotechnology sector and 101.33% lower than that of the Health Care industry. The current valuation for all United States stocks is 100.37% higher than that of the company.
Iteos Therapeutics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Iteos Therapeutics's current stock value. Our valuation model uses many indicators to compare Iteos Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Iteos Therapeutics competition to find correlations between indicators driving Iteos Therapeutics's intrinsic value. More Info.Iteos Therapeutics is rated fourth overall in return on equity category among its peers. It is rated third overall in return on asset category among its peers . Comparative valuation analysis is a catch-all technique that is used if you cannot value Iteos Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Iteos Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Iteos Therapeutics' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Iteos Therapeutics could also be used in its relative valuation, which is a method of valuing Iteos Therapeutics by comparing valuation metrics of similar companies.Iteos Therapeutics is currently under evaluation in current valuation category among its peers.
Iteos Fundamentals
| Return On Equity | -0.35 | ||||
| Return On Asset | -0.18 | ||||
| Current Valuation | (61.62 M) | ||||
| Shares Outstanding | 44.21 M | ||||
| Shares Owned By Insiders | 0.34 % | ||||
| Shares Owned By Institutions | 90.28 % | ||||
| Number Of Shares Shorted | 2.06 M | ||||
| Price To Earning | 50.50 X | ||||
| Price To Book | 0.91 X | ||||
| Price To Sales | 12.78 X | ||||
| Revenue | 35 M | ||||
| EBITDA | (121.82 M) | ||||
| Net Income | (134.41 M) | ||||
| Cash And Equivalents | 791.86 M | ||||
| Cash Per Share | 22.26 X | ||||
| Total Debt | 5.1 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 6.42 X | ||||
| Book Value Per Share | 12.90 X | ||||
| Cash Flow From Operations | (98.18 M) | ||||
| Short Ratio | 1.34 X | ||||
| Earnings Per Share | (4.73) X | ||||
| Target Price | 10.35 | ||||
| Number Of Employees | 173 | ||||
| Beta | 1.49 | ||||
| Market Capitalization | 448.68 M | ||||
| Total Asset | 686.98 M | ||||
| Retained Earnings | (9.78 M) | ||||
| Working Capital | 469.18 M | ||||
| Net Asset | 686.98 M |
About Iteos Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Iteos Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Iteos Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Iteos Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts. Iteos Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 94 people.
Thematic Opportunities
Explore Investment Opportunities
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in producer price index. You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.
Other Consideration for investing in Iteos Stock
If you are still planning to invest in Iteos Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Iteos Therapeutics' history and understand the potential risks before investing.
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Fundamental Analysis View fundamental data based on most recent published financial statements |